Bumetanide acts by inhibiting the Na+-K+-2Cl− cotransporters NKCC1 and NKCC2; it is indicated for the treatment of edema associated with congestive heart failure and hepatic and renal diseases (including nephrotic syndrome) in adults (FDA 2009a), and has a known safety profile (Brater 2000; Howlin and Moss 2012; Wittner et al. 1991). The gene discussed is SLC12A1; the disease is congestive heart failure.